Literature DB >> 9433407

The role of cytokines in Henoch Schonlein purpura.

N Besbas1, U Saatci, S Ruacan, S Ozen, A Sungur, A Bakkaloglu, A M Elnahas.   

Abstract

Serum levels of tumor necrosis factor (TNF) and interleukin(IL-1) were studied in 20 HSP patients, in the acute phase and after remission, by ELISA technique. Skin biopsies obtained during the acute phase both from a lesion and from unaffected skin, as well as during remission, were immunostained for TNF, IL-1, and IL-6. The mean age of the patients was 9.8 (5-13). Mean serum TNF levels during the acute phase and remission were 14.0 +/- 8.9 pg/ml, and 6.8 +/- 2.4 pg/ml, respectively (p < 0.05). Serum TNF levels in patients with renal involvement (18.8 +/- 10.2 pg/ml) were significantly higher than in those without (10.8 +/- 6.5 pg/ml) (p < 0.05). Serum levels of IL-1 in the acute phase and remission were undetectable. All specimens showed leukocytoclastic vasculitis. Immunohistochemical studies revealed TNF, and a less intense IL-1 and IL-6 staining in the nucleated epidermal layer, with a granular, intracellular pattern. Staining was significantly increased in the affected skin during the acute phase. These results suggest that TNF, IL-1, and IL-6 may play a role as a mediator of inflammation in HSP.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9433407     DOI: 10.3109/03009749709065719

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  34 in total

1.  Circulating IgA from acute stage of childhood Henoch-Schönlein purpura can enhance endothelial interleukin (IL)-8 production through MEK/ERK signalling pathway.

Authors:  Y-H Yang; Y-H Huang; Y-L Lin; L-C Wang; Y-H Chuang; H-H Yu; Y-T Lin; B-L Chiang
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

2.  Partial response to anakinra in life-threatening Henoch-Schönlein purpura: case report.

Authors:  Erynn M Boyer; Martin Turman; Kathleen M O'Neil
Journal:  Pediatr Rheumatol Online J       Date:  2011-08-11       Impact factor: 3.054

3.  Leptin levels in Henoch-Schönlein purpura.

Authors:  Yuksel Aliyazicioglu; Ozan Ozkaya; Husamettin Yakut; Ismail Islek; Muhlise Alvur
Journal:  Clin Rheumatol       Date:  2006-07-01       Impact factor: 2.980

4.  Serum amyloid A levels associated with gastrointestinal manifestations in Henoch-Schönlein purpura.

Authors:  Xuelian He; Yulan Zhao; Yin Li; Shixiu Kang; Yan Ding; Jiangwei Luan; Peiwei Zhao; Ningsheng Liu; Wei Yin
Journal:  Inflammation       Date:  2012-08       Impact factor: 4.092

5.  Kidney is in trouble with mediators.

Authors:  Ayse Balat
Journal:  Bosn J Basic Med Sci       Date:  2010-04       Impact factor: 3.363

6.  Investigation of the change in CD4⁺ T cell subset in children with Henoch-Schonlein purpura.

Authors:  Yuan-Yuan Li; Cheng-Rong Li; Guo-Bing Wang; Jun Yang; Ying Zu
Journal:  Rheumatol Int       Date:  2011-12-21       Impact factor: 2.631

7.  Tumour necrosis factor-like weak inducer of apoptosis (TWEAK), an important mediator of endothelial inflammation, is associated with the pathogenesis of Henoch-Schonlein purpura.

Authors:  T Chen; Z-P Guo; M-M Li; J-Y Li; X-Y Jiao; Y-H Zhang; H-J Liu
Journal:  Clin Exp Immunol       Date:  2011-07-15       Impact factor: 4.330

8.  Association between allergic diseases and risks of HSP and HSP nephritis: a population-based study.

Authors:  An-Chyi Chen; Cheng-Li Lin; Te-Chun Shen; Tsai-Chung Li; Fung-Chang Sung; Chang-Ching Wei
Journal:  Pediatr Res       Date:  2015-12-21       Impact factor: 3.756

9.  Production of chemokines in Kawasaki disease, Henoch-Schönlein purpura and acute febrile illness.

Authors:  Hyo Seok Chung; Hyo Young Kim; Hee Sun Kim; Hee Jung Lee; Ji Hyun Yuh; Eun Sil Lee; Kwang Hae Choi; Young Hwan Lee
Journal:  J Korean Med Sci       Date:  2004-12       Impact factor: 2.153

10.  CTLA-4 +49 A/G genotype and HLA-DRB1 polymorphisms in Turkish patients with Henoch-Schönlein purpura.

Authors:  Oguz Soylemezoglu; Harun Peru; Sevim Gonen; Aysun Cetinyurek; Ozan Ozkaya; Sevcan Bakkaloğlu; Necla Buyan; Enver Hasanoglu
Journal:  Pediatr Nephrol       Date:  2008-05-01       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.